Purpose Vincristine is known to interfere with OATPmediated uptake of other compounds, hinting that vincristine itself could be a substrate of OATP transporters. The present study therefore aimed to investigate the role of OATP transporters in the hepatocellular disposition of vincristine. Methods Vincristine uptake was studied in suspended rat and human hepatocytes as well as OATP-transfected Chinese hamster ovary (CHO) cells in the absence and presence of OATP transporter inhibitors. Membrane vesicles containing MDR1 or MRP1/2/3 were used to directly assess the role of these efflux transporters in vincristine disposition. Results Uptake in suspended rat hepatocytes was temperature-dependent and could be inhibited by a range of OATP inhibitors. Furthermore, the MRP-inhibitor benzbromarone, but none of the tested MDR1 inhibitors, reduced vincristine efflux in rat and human suspended hepatocytes. OATP1B1-, OATP1B3-and OATP2B1-transfected CHO cells showed significantly increased vincristine uptake as compared to wild-type cells. Moreover, uptake in OATPtransfected CHO cells was reduced by OATP inhibitors. However, uptake studies in suspended human hepatocytes showed that only 10% of the total vincristine uptake process could be attributed to OATP-mediated transport. Studies with transporter-expressing membrane vesicles confirmed vincristine as an MDR1 substrate, while MRP1/2/3-mediated transport of vincristine could not be observed with this model system. Conclusions Our findings show the involvement of OATP transporters in the disposition of vincristine in rat and human hepatocytes. However, in both species, hepatic uptake is overshadowed by a benzbromarone-sensitive efflux mechanism, possibly MRP3. 
INTRODUCTION
Since its identification in the early 60's in extracts originating from the Catharantus roseus flower (Madagascar periwinkle), vincristine has been a key chemotherapeutic drug for the treatment of both adult and pediatric cancer patients (1) . Vincristine is a cornerstone during the induction, intensification and consolidation phases in the treatment of acute lymphoblastic leukemia (2, 3) . Moreover, it is indicated for Hodgkin lymphoma, nonHodgkin lymphoma, neuroblastoma, rhabdomyosarcoma and Wilms tumor (4). Vincristine cytotoxicity arises from microtubule binding, which disrupts the mitotic spindle during cell division, causing cell cycle arrest and inducing apoptosis (5) . This mechanism of action requires an adequate intracellular exposure. However, intracellular vincristine concentrations are hard to predict due to drug resistance factors such as P-gp/ABCB1/MDR1 and members of the MRP/ABCC family (6) . Additionally, large inter-individual variability in vincristine pharmacokinetics (>30%) as well as a high risk for dose-dependent vincristine-induced neuropathy, hamper selection of a suitable dose (5) . A thorough understanding of vincristine disposition could help identify key mechanisms underlying vincristine pharmacokinetics, pharmacodynamics and toxicity. Incorporation of this information into physiologically-based pharmacokinetic (PBPK) and population-PK models, could aid in improving patientspecific dosing guidelines. Vincristine pharmacokinetics is defined by a large volume of distribution (160 L/m 2 ) and a relatively long terminal elimination half-life (8.2 h), determined primarily by hepatobiliary elimination and to a lesser extent by renal elimination (7) . Initial studies with radiolabeled vincristine showed a 40-fold higher vincristine concentration in the bile as compared to plasma (8) . These studies also indicated that after seventy-two hours, 8 to 15% of the administered dose can be found in urine and about 70% can be recovered from feces, of which 50 to 60% unchanged. Even though only 50% of the administered dose is metabolized, CYP3A5 expression has been inversely correlated with the risk of developing vincristine-induced neuropathy (9) . Additionally, concomitant treatment of vincristine with CYP3A4/5 inhibitors, like the azole-type antifungals, increases the risk for vincristine-induced neuropathy (10) . Notably, CYP3A5-mediated vincristine clearance is 9 to 14-fold higher as compared to CYP3A4-mediated clearance (11) . Consequently, CYP3A4 only contributes significantly to vincristine metabolism in CYP3A5 non-expressers (11) (12) (13) . Apart from CYP3A4/5, vincristine is also a substrate for several ABC-transporters i.e.: P-gp/ABCB1/ MDR1 (14) , MRP1/ABCC1 (15) and MRP2/ABCC2 (16) . Furthermore, presence of MRP3/ABCC3 (17) , MRP7/ ABCC10 (18) , ABCB6 (19) and RALBP1 (20) have been shown to increase resistance to vincristine toxicity. Resistance to chemotherapeutics due to (enhanced) expression and action of efflux transporters received a lot of attention in the past. More recently, the importance of SLC-transporters for the uptake of chemotherapeutics into tumor cells and for pharmacokinetics of chemotherapeutics has also gained a lot of interest (21) (22) (23) . Overexpression of SLC-transporters (e.g. OATP1B3) in certain cancer types could sensitize tumor cells for chemotherapeutics which are substrates of these uptake transporters. Yet, apart from the chemo-sensitizing effect of the kidneyspecificOCT3/SLC22A3 transporter in kidney carcinoma cell lines (24) , no uptake transporter has been linked to vincristine disposition. Nevertheless, some reports show that vincaalkaloids can accumulate strongly in HL-60 cells and interact with carrier-mediated processes in rat/human hepatocytes and murine leukemia cells (25) (26) (27) (28) . Additionally, vincristine has been shown to interfere with OATP1B1-and OATP1B3-mediated substrate transport (29) (30) (31) . Therefore, the aim of the present work was to investigate whether hepatic isoforms of the OATP transporter family play a role in the hepatocellular disposition of vincristine in rat and human hepatocytes.
MATERIALS AND METHODS

Materials
Vincristine-sulfate was acquired from LC chemicals (Woburn, Massachusetts); vinblastine (1 mg/ml) as well as methotrexate (2.5 mg/ml) were obtained from TEVA Pharma Belgium (Wilrijk, Belgium). Atazanavir-sulfate was obtained through the NIH Aids Reagent Program. Benzbromarone, bromosulphophthalein, 5 (6)-Carboxy-2′,7′-dichlorofluorescein (CDCF), digoxine, glibenclamide, losartan, paclitaxel, paraffin oil, L-proline, rifampycine, rifamycine SV and silicon oil (AP150) were purchased from Sigma-Aldrich (Schnelldorf, Germany). Dulbecco's modified eagle medium (DMEM; 1 g/ L glucose, 25 mM HEPES), fetal bovine serum (heatinactivated) (FBS), L-glutamine (200 mM), Hanks' Balanced Salt Solution (HBSS), penicillin-streptomycin mixture (10,000 IU potassium penicillin and 10,000 IU streptomycin sulfate per ml in 0.85% saline), phosphate buffered saline (PBS), trypsine-EDTA mixture (170 U/ml and 200 mg/L, respectively) and Trypan blue stain (0.4%) were obtained from Westburg (Leusden, The Netherlands). Dimethylsulfoxide (DMSO), methanol (MeOH) and Na-pyruvate were purchased from Acros Organics (Geel, Belgium). CaCl 2 and NaHCO 3 were obtained from Chem-lab NV (Zedelgem, Belgium) and NaCl from Fisher Chemical (Landsmeer, The Netherlands). Geneticine-sulfate was purchased from Life Technologies (Paisley, UK) and HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) from MP Biochemical (Illkrich, France). MgCl 2 .7H 2 O was obtained from AnalarNormapur(VWR) (Leicestershire, England) and KCl from AppliChem GmbH (Darmstadt, Germany). Cyclosporine A was purchased from Sequoia Research Products LTD (Pangbourne, UK). MK571 was obtained from Merck chemicals (Overijse, Belgium) and docetaxel from Avantis Pharma (Diegem, Belgium). Quinidine-sulfate was purchased from Unibios lab (Mumbai, India) and Formic acid (LC-MS grade) from Biosolve-chemicals (Valkenswaard, The Netherlands). Control, MRP1, MRP2, MRP3 and MDR1 inside-out membrane vesicles were purchased from ThermoFisher Scientific (Waltham, MA USA). Estradiol 17-(β-D-Glucuronide) was purchased from Sanbio (Uden, The Netherlands).
Animals
Male Wistar rats were purchased from Janvier (Le Genest Saint Isle, France) and housed according to Belgian and European laws, guidelines and policies for animal experiments, animal housing, and animal care in the Central Animal Facility of the KU Leuven. All experiments involving lab animals were approved by The Institutional Ethical Committee for Animal Experimentation (license number: LA 1210261).
Vincristine Uptake in Suspended Rat Hepatocytes
Suspended hepatocytes from Wistar rats (190-200 g) were isolated according to the two-step collagenase perfusion method, cryopreserved and thawed as described previously (32) . Freshly-isolated hepatocytes were suspended in KrebsHenseleit buffer (KHB) (118 mM NaCl; 5.17 mM KCl; 1.2 mM CaCl 2 ; 1.2 mM MgCl 2 ; 23.8 mM NaHCO 3 ; 12.5 mM HEPES; 11.1 mM Glucose; 5 mM Na-pyruvate; pH 7.4) sparged with carbogen (95%:5% O 2 :CO 2 ) and kept at 4°C until the start of the experiment. Viability and cell density were evaluated using the Trypan blue (0.04%) exclusion method and counting on a hemocytometer. Viability of freshly-isolated hepatocytes ranged between 90 and 92% and viability of cryopreserved hepatocytes was 81%. Cells were diluted to a two-fold concentrated cell density (2 million cells/ml) before the start of experiments. Incubations were initiated by adding 175 μL of four-fold concentrated inhibitor solution to 350 μL of the two-fold concentrated cell suspension in a glass test tube and pre-incubating for 10 min at 37°C. Following the pre-incubation, 175 μl of four-fold concentrated (2 μM) vincristine solution in KHB was added. Uptake of vincristine in suspended rat hepatocytes was linear as a function of time up to 3 min (data not shown). After 3 min, three 200 μL aliquots of the incubate were layered on top of 700 μL of oil (82:18 silicon oil AP150:paraffin oil; density 1.051 g/ml) which itself had been layered on top of 300 μL of 8% NaCl solution in 1.5 ml centrifuge tubes. Tubes were centrifuged immediately for 3 min at 16,162 g. Following centrifugation, centrifuge tubes were placed in ethanol cooled with dry ice (−80°C), where they were kept until the end of the experiment. After finishing the experiments, the bottom of the tubes were cut (± 80 μL) and collected in glass test tubes. Pellets were lysed by shaking them for thirty minutes after adding 300 μL of 70:30 MeOH:H 2 O containing 2.5 nM of the internal standard (vinblastine). After the pellets were completely disrupted, lysates were collected in 1.5 ml centrifuge tubes and stored at −80°C until the day of analysis.
Culturing of Chinese Hamster Ovary Cells
Wild-type, OATP1B1-, OATP1B3-, and OATP2B1-transfected CHO cells were cultured at passage numbers 75-77, 67-69, 67-69 and 27-29, respectively. The CHO cells were grown in a humidified incubator (37°C, 5% CO2) in T-75 cm 2 culture flasks (Greiner Bio-One, Wemmel, Belgium) containing 15 ml of culture medium. Culture medium consisted of DMEM (1 g/L glucose; 25 mM HEPES) supplemented with 10% FBS, 50 μg/ml L-proline, 100 U/ ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 110 μg/ml sodium pyruvate. Medium of OATPtransfected cells was supplemented with 500 μg/ml of geneticin. When cells were 90-100% confluent, culture medium was removed and cells were washed two times with 1.5 ml of trypsine-EDTA mixture, prewarmed at 37°C. This was followed by adding 2 ml of the trypsine-EDTA mixture to the cells and keeping them in a humidified incubator (37°C, 5% CO 2 ) for 4 min. After cells were detached, trypsinization was stopped by adding 8 ml of culture medium. Cells were counted on a hemocytometer and subcultered at a ratio depending on the acquired cell count. In preparation of uptake experiments, cells were seeded at a density of 20,000-25,000 per well in Advanced TC™ 24-well plates (Greiner Bio-One, Wemmel, Belgium). Medium was replaced every other day and experiments were performed after CHO-cells reached 90-100% confluence on day four after seeding. One day before the experiments, CHO-cells were treated with 5 mM of sodium butyrate in culture medium to induce gene expression.
Vincristine Uptake in Transfected Chinese Hamster Ovary Cells
On the day of experiments, cell morphology and confluence were visually checked. Cells were washed twice with 0.5 ml/ well of warm (37°C) HBSS (10 mM HEPES, pH 7.4) and preincubated for 10 min with 250 μL of warm (37°C) KHB with or without a two-fold concentrated uptake transporter inhibitor solution (20 μM). Following pre-incubation, 250 μL of warm (37°C) two-fold concentrated vincristine solution (20 μM; KHB) was added. Linearity studies were performed to ensure linear uptake of vincristine for at least 3 min (data not shown). After 3 min, the incubate was aspirated and cells were washed four times with ice-cold (4°C) HBSS (10 mM HEPES, pH 7.4). Subsequently, cells were lysed for thirty minutes with 300 μl of 70:30 MeOH:H 2 O containing 2.5 nM of vinblastine as internal standard. Lysates were transferred to 1.5 ml centrifuge tubes and stored at −80°C until the day of analysis. A control plate was included which was incubated with a positive control (sodium fluorescein) to verify OATP activity (data not shown). Cells in the control plate were lysed with 300 μL of 0.5% Triton-X in PBS. These lysates were used to measure the protein content using a BCA Protein Assay kit (Pierce Chemical, Rockford, IL, USA), enabling normalization of uptake rates for protein content. Uptake of vincristine in wild-type (Wt)-cells was subtracted from uptake of vincristine in transfected CHO-cells to calculate the net uptake, which equals the transporter-mediated component of vincristine in the OATP-transfected CHOcells.
Vincristine Uptake in Suspended Human Hepatocytes
Cryopreserved human hepatocytes were acquired in collaboration with BioreclamationIVT® (Brussels, Belgium). Human hepatocytes donor information per batch is shown in Table I . Cells were stored in liquid nitrogen (−196°C) until the day of experiments. On the day of the experiment, cells were thawed by gently shaking the vial in a water bath (37°C). When frozen liquid was no longer present, the content of the vial was transferred completely into a 50 ml Falcon® tube containing warm ( 3 7°C ) I n V i t r o G R O ™ H T t h a w i n g m e d i u m (BioreclamationIVT®, Brussels, Belgium). The hepatocyte suspension was centrifuged for 5 min (50 g) at 21°C, supernatant was aspirated and the pellet gently resuspended in 1 ml of warm (37°C) KHB. Viability and cell density were evaluated using the Trypan blue (0.04%) exclusion method and counting on a hemocytometer. Viability of human hepatocytes ranged between 80 and 92%. Prior to the experiment, cells were diluted to a two-fold concentrated cell density (2 million cells/ml). Pre-incubation and uptake experiments were performed similar to uptake experiments performed with SRH. However, contrary to the oil-spin method applied with SRH, direct centrifugation was applied for SHH. This was done because benzbromarone decreased the passage of SHH through the oil-layer in a concentration dependent manner (data not shown). After 1 min incubations, 200 μL aliquots were transferred to 1.5 ml centrifuge tubes which were centrifuged for thirty seconds at 16,162 g. Next, supernatants were aspirated and pellets were washed with ice cold (4°C) PBS, followed by a repetition of the centrifugation step. Following centrifugation, the PBS was aspirated and 300 μL of ice cold (4°C) 8% NaCl was added on top of the pellets. After a final centrifugation, centrifuge tubes were placed in ethanol cooled with dry ice (−80°C), where they were kept until the end of the incubations. After finishing the experiments, the bottom of the tubes were cut (± 80 μL) and collected in glass test tubes. Pellets were lysed by shaking them for thirty minutes after adding 300 μL of 70:30 MeOH:H2O containing 2.5 nM of the internal standard (vinblastine). After the pellets were completely disrupted, lysates were collected in 1.5 ml centrifuge tubes and stored at −80°C until the day of analysis.
Vincristine Uptake in Inside-Out Membrane Vesicles
Just before the experiment, vesicles (control, MRP1, MRP2, MRP3, MDR1) were thawed by gently shaking in a water bath (37°C) and were kept on ice (4°C) until dilution. Prior to experiments, vesicles (5 mg/mL) were diluted in vesicle uptake buffer (50 mM MOPS-TRIS; 70 mM KCl; 7.5 mM MgCl 2 ; pH 7) and dispensed (29 μL) in 2 mL Eppendorf (14) . Wells of all other substrates were washed 5 times with 200 μL of icecold stop buffer. Control wells were included to assess the extent of substrate binding to the filter plate, the blank and the start-solution. Vincristine samples were solubilized using 50 μL of 70:30 MeOH:H 2 O containing 10 nM of the internal standard (vinblastine). E17BDG samples were solubilized using 50 μL of 70:30 MeOH:H 2 O. CDCF samples were solubilized using 50 μL of 10% w/v SDS. After addition of the correct solubilizing agent, filter plates were placed on top of a 96-well receiver plate and centrifuged for 1 min at 850 g (21°C). Following centrifugation, the solubilizing and centrifugation step were repeated once more. For compounds analyzed by LC-MSMS, vincristine and E17BDG, 80 μL of filtrate was transferred to deep-well 96-well plates and evaporated under a gentle stream of N 2 (45°C). Samples were dissolved using 50:50 ACN:H 2 O, centrifuged and injected onto the LC-MSMS system. Eighty microliter of samples containing CDCF were diluted with 100 μL of NaOH (0.1 M) and analyzed using fluorescence spectroscopy (Ex: 485 nm, Em: 535 nm; Spectramax ® M2).
Bioanalysis
On the day of analysis, samples were thawed, vortexed and centrifuged (20, ) with retention times of 3.02 and 3.14 min for vincristine and vinblastine, respectively. Other ionization parameter settings were: capillary temperature (275°C), vaporizing temperature (300°C), sheet gas pressure (30 arbitrary units), auxiliary gas pressure (25 arbitrary units) and ion sweep gas pressure (0 arbitrary units). Collision energies were 23 and 18 arbitrary units for vincristine and 24 and 17 arbitrary units for vinblastine, respectively. Quality control concentrations were 0.2 μM, 0.02 μM and 0.002 μM for SRH/CHO samples, and 0.1 μM, 0.01 μM and 0.001 μM for SHH samples. Intra-and interday precision of quality control samples were below 10% for the high and middle concentrations and <15% for the low concentration. The calibration curves were linear over 12 points ranging from 500 to 0.25 nM and from 250 to 0.13 nM for SRH/ CHO and SHH samples, respectively.
Data-Analysis
ANOVA (α level of 0.05; Dunnett's post hoc test) was applied to compare control conditions to experiments including inhibitors, using Graphpad Prism ® version 5.00 for windows (GraphPad Software, Inc., California, USA). The ShapiroWilk test for normality was applied to test the distribution of SHH data for normality. Subsequently, a grouped two-way Student's t-test was applied (α level of 0.05) to the overall averages to compare the populations with and without inhibitor.
Uptake data from CHO-cell experiments were used to estimate the OATP-mediated uptake clearance of vincristine in SHH as reported by De Bruyn and coworkers (Eq. 1)(33).
Cl OATP1B1/3,SHH is the uptake clearance of vincristine by either OATP1B1 or OATP1B3 predicted for SHH. Cl OATP1B1/3,CHO is the uptake clearance of vincristine in either OATP1B1-or OATP1B3-transfected CHO cells and RAF OATP1B1/3 is the relative activity factor determined for OATP1B1 or OATP1B3 transfected CHO cells with estrone-3-sulfate and CGamF, respectively (Table II) . RAFfactors determined by De Bruyn and coworkers were determined on the same OATP-transfected CHO cells as applied in the present study and a pool of human hepatocytes (Table I) (33) . Therefore, we deemed it was justifiable to use the same RAF-factors as determined by De Bruyn and coworkers to recalculate the uptake data acquired in CHO cells.
Passive uptake clearance of vincristine in SHH cells (Cl passive,SHH ) was estimated from vincristine uptake clearance in wild-type CHO cells (Cl Wt,CHO ). After dividing the surface area of CHO cells by the surface area of SHH, a factor of 0.51 was obtained (33) . This factor was applied according to Eq. 2 to correct the Cl Wt,CHO for the difference in surface area across which passive permeation can occur. Thus, Cl passive,SHH was calculated:
RESULTS
Vincristine Uptake in Suspended Rat Hepatocytes
Uptake of vincristine in SRH was found to be temperaturedependent: uptake at 4°C [2.2 ± 0.5 pmol/(min × million cells)] was significantly lower than uptake at 37°C [5.58 ± 0.5 pmol/(min × million cells)] (Fig. 1) . Additionally, uptake of vincristine in SRH could be inhibited with known inhibitors of OATP-mediated transport (10 μM) as shown in Fig. 1 (atazanavir, bromosulfophthalein, cyclosporine A, docetaxel, glibenclamide, losartan, MK571, methotrexate, paclitaxel, rifampicin, rifamycin SV). However, no statistically significantly different uptake was observed when vincristine was incubated in the presence of digoxin or quinidine. Increasing concentrations of known MRP inhibitors MK571 and benzbromarone significantly increased the intracellular accumulation of vincristine in SRH ( Fig. 2a and b) .
However, at low concentrations (10 μM) MK571 also inhibited vincristine uptake.
Vincristine Uptake in OATP1B1/1B3/2B1-Transfected Chinese Hamster Ovary Cells
The uptake of vincristine was investigated in CHO cells transfected with human OATP1B1, 1B3 and 2B1 and compared to uptake in wild-type CHO cells. Under these conditions, uptake of vincristine was significantly higher in all of the OATP-transfected CHO cells as compared to the uptake in wild-type CHO cells (Figs. 3a) . Interestingly, uptake in OATP1B3-transfected cells [77.7 ± 6.4 pmol/(min x mg protein)] was noticeably higher than the uptake in OATP1B1-[39.6 ± 5.7 pmol/(min x mg protein)] and 2B1-transfected cells [39.3 ± 4.6 pmol/(min x mg protein)]. Additionally, uptake of vincristine could be significantly inhibited with known inhibitors of OATP-mediated transport (10 μM) as shown in Fig. 3b-d (atazanavir, docetaxel, digoxin, losartan, methotrexate, paclitaxel, rifamycin SV, benzbromarone). Vincristine uptake could not be saturated in any of these cell lines when incubated at concentrations up to 300 μM (data not shown).
In view of clinical relevance, higher concentrations of vincristine were not evaluated.
Vincristine Uptake in Suspended Human Hepatocytes
Effect of temperature, rifamycin SV and benzbromarone on the uptake of vincristine in suspended human hepatocytes was (Figs. 4a-c) . In all batches of human hepatocytes, a significant decrease of vincristine uptake was observed at 4°C when compared to experiments performed at 37°C (Fig. 4a) . However, the effect of 10 μM rifamycin SV on vincristine uptake in SHH was only statistically significant in one batch of human hepatocytes (HRU; p = 0.0057), in which it decreased by 52.5%. In all other batches, vincristine uptake decreased by approximately 10% in the presence of 10 μM rifamycin SV, but these changes were not statistically significant (Fig. 4b) . Also, increasing the rifamycin SV concentration to 100 μM did not significantly alter vincristine uptake in SHH (data not shown). Still, in the presence of 100 μM benzbromarone, vincristine uptake increased to 407 ± 105% in all batches of SHH as compared to the control condition (p < 0.0001), suggesting an involvement of an MRP-mediated efflux process. Vincristine uptake data from OATP-transfected CHO cells were converted for comparison with uptake data obtained in SHH, by using previously reported RAF factors (Table III) (33) . A good match was observed between passive uptake clearance estimated from uptake in wild-type CHO cells [4.1 ± 0.5 μl/(min × million cells)] and passive uptake clearance observed in SHH at 4°C [3.8 ± 1.3 μl/(min × million cells)]. However, a big difference was observed between active uptake clearance predicted from CHO cells [1.9 ± 0.3 μl/(min × million cells)] and the measured active uptake clearance [10.1 ± 1.5 μl/(min × million cells)]. The predicted OATP-mediated uptake clearance in SHH [1.9 ± 0.3 μl/(min × million cells)] only amounted to 14% of the observed total uptake clearance in SHH. However, this corresponds to the small (10%) but statistically insignificant change in vincristine uptake in the presence of the OATP transporter inhibitor rifamycin SV in SHH.
Identification of the Benzbromarone-Sensitive Efflux Transporter
Effect of 2 μM of MDR1 inhibitors elacridar, tariquidar and valspodar was assessed on the uptake of vincristine (Fig. 5 ) in cryopreserved suspended rat and human hepatocytes to rule out the contribution of P-gp in vincristine efflux in suspended hepatocytes. No significant effect was observed of the MDR1 inhibitors on the uptake of vincristine whereas benzbromarone (100 μM) increased the uptake of vincristine in both species. To evaluate which MRP transporter could be involved in vincristine disposition in suspended hepatocytes, uptake of vincristine was assessed in MRP1, MRP2 and MRP3 inside-out membrane vesicles (Fig. 6 ). No significant difference was observed in the uptake of vincristine in the presence of either ATP or AMP. To validate the vesicle assay for assessing vincristine efflux, we showed that in MDR1 vesicles vincristine uptake was significantly different in the presence of ATP (Fig. 6)(14) . Still, benzbromarone inhibited the ATP-dependent uptake of E17BDG and CDCF in MRP1, MRP2 and MRP3 vesicles (Fig. 7) . It is noteworthy that the absolute difference between CDCF uptake in control and MRP3 vesicles was low [22 pmol/(min x mg protein)] as compared to CDCF uptake in MRP2 vesicles.
DISCUSSION
Notwithstanding the fact that vincristine is one of the oldest anticancer drugs currently being used in clinical practice, some questions regarding vincristine pharmacokinetics remain unanswered (5) . With respect to hepatic uptake, several studies during the early 90's investigated the uptake processes of vinca-alkaloids vincristine and vinblastine in human and rat hepatocytes. Based on these studies, the authors concluded that an energy-independent non-saturable passive diffusion process and an energy-dependent saturable active transport system may be involved in the uptake of vinca-alkaloids(34). More recently, several publications reported the interference of vincristine with OATP1B1 and OATP1B3-mediated uptake processes (30, 31) . Additionally, in a thesis by T. Loo in 2011, SNPs in genes coding for SLCO1B1 and SLCO1B3 were positively correlated with the manifestation of vincristine-induced neurotoxicity (35) . The present work was therefore aiming to elucidate the potential role of several isoforms of the OATP transporter family in the hepatocellular distribution of vincristine.
Experiments with suspended rat hepatocytes clearly showed that vincristine uptake was temperature-dependent, with a 7.6-fold lower uptake at 4°C (Fig. 1) . These data are in line with temperature-dependent uptake of vinblastine (2.6-fold lower uptake at 4°C) as shown by Zhou and coworkers (27) . However, temperature-dependency not necessarily indicates that a transporter-mediated process is involved, since membrane fluidity may be reduced at 4°C (36, 37) . To identify whether vincristine uptake was in fact mediated by one or more transporters, uptake experiments were performed in the presence of several known OATP inhibitors (Fig. 1) . Paclitaxel and docetaxel exhibited the most pronounced effect on vincristine uptake, confirming the strong interaction of taxanes with OATP transporters (30, 31) . Inhibition of vincristine uptake in SRH by methotrexate is in line with research performed by Smeland et al., who suggested a competitive interaction between vincristine and methotrexate in SRH (29) . However, digoxin and quinidine, both OATP1A4/ Slc21a5 inhibitors, were unable to significantly alter the vincristine uptake process (38) . This indicates that vincristine is probably not a good substrate of OATP1A4. All other OATP inhibitors (atazanavir, bromosulfophthalein, cyclosporine A, glibenclamide, losartan, rifampicin and rifamycin SV) inhibited vincristine uptake to a similar extent (40% decrease). Even the well-known MRP inhibitor MK571 was able to reduce vincristine entry into SRH. This was not unexpected, since several research groups have reported that MK571 is a potent inhibitor of OATP transporters (31) . Uptake experiments of vincristine in OATP1B1-, 1B3-and 2B1-transfected CHO cell lines resulted in a higher vincristine uptake as compared to wild-type CHO cells (Fig. 3a) . Additionally, uptake of vincristine in transfected CHO cells could be inhibited with a series of OATP transporter inhibitors (Figs. 3b-d) . OATP- mediated uptake of vincristine proved to be non-saturable with concentrations up to 300 μM (data not shown). Uptake data of vincristine in OATP1B1-and OATP1B3-transfected CHO cells were converted for comparison with SHH data by using RAF factors which were determined previously by our group (33) . Passive uptake data estimated from vincristine uptake in wild-type CHO cells [4.1 ± 0.5 μl/(min × million cells)] corresponded well to passive uptake clearance observed in SHH at 4°C [3.8 ± 1.3 μl/(min × million cells)] (Table III) . However, uptake measurements obtained at 4°C likely underestimate true passive uptake due to increased membrane rigidity at low temperature (36, 37) . RAF-corrected total uptake clearance [1.9 ± 0.3 μl/(min × million cells)] valued 15% of the observed total uptake clearance in SHH [13.9 ± 3.7 μl/ (min × million cells)]. This appears consistent with the fact that uptake of vincristine in SHH could not be inhibited below 90%, using an established OATP transporter inhibitor such as rifamycin SV (Fig. 4b) . It is still plausible that rifamycin SV simultaneously inhibited uptake as well as efflux transport (39) . As a consequence, inhibition of vincristine uptake would be counteracted by the inhibition of vincristine efflux transport, resulting in an insignificant net decrease of 10%. Also, involvement of another unidentified uptake transporter could explain the large observed difference between uptake at 37°C and 4°C which was not explained by the inhibition of OATP. In view of the relatively large size of vincristine, the involvement of OAT2 in hepatic uptake of vincristine can be considered less likely, although we cannot exclude this based on the presently available data. Still, rifamycin SV statistically significantly decreased vincristine uptake in one batch of SHH by 52.5%. It is also possible that this individual (Asian; male; 55 years old) carries a SNP in one of the OATP-coding genes, corresponding to a phenotype with increased vincristine uptake. On the other hand, the benzbromarone-sensitive efflux transporter may have been less active in this individual, thus improving conditions to observe OATP inhibition in the presence of rifamycin SV.
Apart from the observed uptake inhibition, increasing concentrations of MK571 and benzbromarone significantly increased the uptake of vincristine in SRH (Figs. 2a-b) . This contrasts to a previous study of Zhou and coworkers, where it was suggested that vincristine efflux in suspended hepatocytes was limited (27) . Similar results were obtained in SHH in the presence of 100 μM of benzbromarone (Fig. 4c) . Both MK571 and benzbromarone are established MRP transporter inhibitors, implying the role of an MRP transporter in the hepatic disposition of vincristine (40) . Cis-stimulation of the OATP-mediated uptake by benzbromarone was ruled out, since it did not increase the uptake of vincristine in the OATP-transfected-CHO cells (41) . Since vincristine is a well-known MDR1 substrate, we needed to show that benzbromarone and MK571 did not inhibit MDR1 in (Fig. 5 ). This is in line with the internalization of MDR1 in suspended hepatocytes as reported by Bow and coworkers (42) . Involvement of BCRP was also excluded since it was reported that BCRP did not confer resistance to vincristine and internalization of MDR1 would also imply the internalization of other canalicular transporters. Among the MRP transporters, it was reported in literature that MRP4, MRP5 and MRP6 expression in transfected cell lines did not induce resistance to vincristine toxicity (43) (44) (45) .
On the other hand, it is well known that vincristine is a substrate of MRP1. Yet hepatic MRP1 expression levels in adult hepatocytes are generally considered low or nondetectable (46) . This reduces the likelihood for MRP1 to have a considerable impact on hepatic drug disposition. Presence of MRP2 had also shown to confer resistance to vincristine toxicity (16, (47) (48) (49) . But, since we were unable to increase vincristine accumulation in the presence of MDR1-selective inhibitors, we hypothesized that MRP2 would likewise not be present or active on the membrane of suspended hepatocytes (42) . Several reports claim that expression of MRP3 could be linked to vincristine resistance; however literature reports on MRP3-mediated vincristine transport are unclear (50) (51) (52) (53) . Taken together, it seems that MRP3 is the only known transporter present in suspended hepatocytes likely to mediate vincristine efflux. To verify which transporter mediated vincristine efflux, vincristine uptake was assessed in membrane vesicles containing MRP1, MRP2, MRP3. However, we were not able to detect the transport of vincristine by MRP1, MRP2 or MRP3 (Fig. 6 ). To ensure that the vesicle assay is a suitable system to measure vincristine transport, we showed that we were able to measure the ATP-dependent transport of vincristine by MDR1. Still, the hydrophobic nature of vincristine could hinder the accurate measurement of vincristine transport in MRP1, MRP2 and MRP3 containing membrane vesicles. It is known that it is challenging to assess efflux transport of hydrophobic compounds in inside-out membrane vesicles (54) . Due to this drawback of the in vitro system, we do not exclude that vincristine is transported by MRP1, MRP2 or MRP3. It may also be possible that the expression levels of MRP3 were too low in the currently used membrane vesicles to measure the transport of vincristine. Indeed, CDCF transport in control and MRP3 containing vesicles did not differ greatly but the uptake could still be inhibited by benzbromarone (Fig. 7) . In a thesis by Loo in 2011, a wide range of ABC transporters were significantly correlated with vincristine neurotoxicity (ABCA4, ABCB5, ABCG1, ABCC4, ABCA1, ABCC1/6, ABCB1, ABCC8, ABCC3, ABCC10, ABCC2) (35) . Instead of toxicity studies, actual transport of vincristine should be evaluated in transfected cell lines or membrane vesicles containing other transporters to identify which transporters are involved. Alternatively, inhibition studies with selective MRP inhibitors could help to identify this elusive efflux transporter. A transporter of the MRP family likely corresponds to the unidentified efflux transporter since benzbromarone and MK571 are notorious MRP inhibitors. However, MRP transporters require ATP for their activity and Watanabe and coworkers reported no change in the uptake of vincristine in SRH upon depletion of ATP (55) . Thus, an ATP-independent benzbromarone-sensitive efflux transporter, not related to the MRP family, may also be responsible for vincristine efflux in SRH (e.g. MATE1, OSTα/β). Further research is therefore warranted to elucidate the identity of this important transporter for hepatocellular vincristine disposition.
CONCLUSION
In conclusion, OATP transporters are involved in the disposition of vincristine in suspended rat and human hepatocytes. However, efflux transport, potentially by the sinusoidal efflux transporter MRP3, overshadows the effect of OATP-mediated transport. The exact role of uptake and efflux transporters should be further investigated to enable mechanistic modeling of vincristine disposition. The present and future findings on vincristine disposition pathways could help researchers to explain the large interindividual variability in vincristine exposure and improve patient-specific dose selection. 
ACKNOWLEDGMENTS AND DISCLOSURES
